AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30917531 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 100,000 IU oral solution in ampoule (Group 2)
Number of subjects: 53
Study 30917531 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 53
Study 28419661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 85
Study 28419661 — intervention group
Group type: COMPARATOR
Intervention: Non‐directive supportive counselling (NDC)
Number of subjects: 85
Study 26485251 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized communication techniques
Number of subjects: 13
Study 26485251 — intervention group
Group type: COMPARATOR
Intervention: Nonstandard communication
Number of subjects: 13
Study 24806873 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise Protocol of Treating Pain (individual daily pain treatment with paracetamol, extended release morphine, buprenorphine transdermal patch or pregabaline for 8 weeks)
Number of subjects: 352
Study 24806873 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise Protocol of Treating Pain
Number of subjects: 352
Study 24806873 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 352
Study 22027909 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 10
Study 22027909 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 10
Study 22027909 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up (FDG-PET/CT)
Number of subjects: 10
Study 19050388 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug conservation (episodic use of antiretroviral therapy guided by CD4 cell count)
Number of subjects: 499
Study 19050388 — intervention group
Group type: COMPARATOR
Intervention: Viral suppression (continuous antiretroviral therapy)
Number of subjects: 499
Study 17608870 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home palliative care
Number of subjects: 298
Study 14872248 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated system (Yoko 232 grip and Yoko 232 strap)
Number of subjects: 11
Study 14872248 — intervention group
Group type: COMPARATOR
Intervention: Modern system (Swix PC grip and SR94 strap)
Number of subjects: 11
Study 14872248 — intervention group
Group type: COMPARATOR
Intervention: Traditional system (Swix PC grip and simple strap)
Number of subjects: 11
Study 12241778 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin-impregnated dog collars
Number of subjects: 1141
Study 12241778 — intervention group
Group type: COMPARATOR
Intervention: Control (no collars)
Number of subjects: 1141
Study 9432075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen
Number of subjects: 200
Study 9432075 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine
Number of subjects: 200
Study 9432075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 200
Study 9432075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 8207744 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg per day
Number of subjects: 301
Study 8207744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 2686457 — intervention group
Group type: EXPERIMENTAL
Intervention: NET (A) (Ortho‐Novum 7/7/7)
Number of subjects: 0
Study 2686457 — intervention group
Group type: EXPERIMENTAL
Intervention: NET (B) (Tri‐Norinyl)
Number of subjects: 0
Study 2686457 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG (Tri‐Levlen)
Number of subjects: 0
Study 2686457 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30794284 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week postoperative rehabilitation program in Nursing Care Facilities (NCFs)
Number of subjects: 240
Study 30794284 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 27432436 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated FVRCP vaccine
Number of subjects: 24
Study 27432436 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified live FVRCP vaccine
Number of subjects: 24
Study 27432436 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 24
Study 24893681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharpen filter
Number of subjects: 40
Study 24893681 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Emboss filter
Number of subjects: 40
Study 24893681 — intervention group
Group type: COMPARATOR
Intervention: Original images
Number of subjects: 40
Study 24893681 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative filter
Number of subjects: 40
Study 24893681 — intervention group
Group type: EXPERIMENTAL
Intervention: Shadow filter
Number of subjects: 40
Study 24662901 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized joint hypermobility (JH)
Number of subjects: 272
Study 24662901 — intervention group
Group type: COMPARATOR
Intervention: Control (non-JH)
Number of subjects: 272
Study 21493292 — intervention group
Group type: EXPERIMENTAL
Intervention: Envoy Esteem Totally Implantable Hearing System
Number of subjects: 57
Study 21493292 — intervention group
Group type: COMPARATOR
Intervention: Control (best-fit aided hearing aids)
Number of subjects: 57
Study 19548437 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonotherapy with Chinese drugs for detoxifying
Number of subjects: 148
Study 19548437 — intervention group
Group type: COMPARATOR
Intervention: Hormonotherapy alone
Number of subjects: 148
Study 16426798 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptotherapy treatment (5 sessions of 45 minutes each)
Number of subjects: 31
Study 16426798 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (control group)
Number of subjects: 31
Study 14707013 — intervention group
Group type: EXPERIMENTAL
Intervention: High exercise level (Hex; approximately 4 MJ/day) with high-fat diet (HF; 50% of energy, 700 kJ/100 g)
Number of subjects: 8
Study 14707013 — intervention group
Group type: EXPERIMENTAL
Intervention: High exercise level (Hex; approximately 4 MJ/day) with low-fat diet (LF; 20% of energy, 300 kJ/100 g)
Number of subjects: 8
Study 14707013 — intervention group
Group type: COMPARATOR
Intervention: No exercise (Nex; control) with high-fat diet (HF; 50% of energy, 700 kJ/100 g)
Number of subjects: 8
Study 14707013 — intervention group
Group type: COMPARATOR
Intervention: No exercise (Nex; control) with low-fat diet (LF; 20% of energy, 300 kJ/100 g)
Number of subjects: 8
Study 14707013 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF; 50% of energy, 700 kJ/100 g)
Number of subjects: 8
Study 14707013 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF; 20% of energy, 300 kJ/100 g)
Number of subjects: 8
Study 14707013 — intervention group
Group type: EXPERIMENTAL
Intervention: High exercise level (Hex; approximately 4 MJ/day)
Number of subjects: 8
Study 14707013 — intervention group
Group type: COMPARATOR
Intervention: No exercise (Nex; control)
Number of subjects: 8
Study 11411815 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/day
Number of subjects: 453
Study 11411815 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10 mg/day
Number of subjects: 453
Study 9432096 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% incline during min 5-15 (Run A)
Number of subjects: 6
Study 9432096 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% incline during min 20-30 (Run B)
Number of subjects: 6
Study 9432096 — intervention group
Group type: COMPARATOR
Intervention: Control (0% grade)
Number of subjects: 6
Study 8518048 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 0
Study 8518048 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 0
Study 2830952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (DHAD)
Number of subjects: 69
Study 2830952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP)
Number of subjects: 69
Study 2830952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (DHAD) and Cisplatin (DDP)
Number of subjects: 69
Study 31843251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT)
Number of subjects: 691
Study 31843251 — intervention group
Group type: COMPARATOR
Intervention: No pharmacomechanical catheter-directed thrombolysis (no PCDT)
Number of subjects: 691
Study 28793785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial aid intervention (photographic representation of medications, indications, and dosing schedule)
Number of subjects: 46
Study 28793785 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic visit discharge medication list (control)
Number of subjects: 46
Study 26420825 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry (GAT) by two ophthalmologists (group 1)
Number of subjects: 100
Study 26420825 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry (GAT) by two non-ophthalmologists (group 2)
Number of subjects: 100
Study 26420825 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry (GAT) by one ophthalmologist and one non-ophthalmologist (group 3)
Number of subjects: 100
Study 26420825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry (DCT) by two ophthalmologists (group 1)
Number of subjects: 100
Study 26420825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry (DCT) by two non-ophthalmologists (group 2)
Number of subjects: 100
Study 26420825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry (DCT) by one ophthalmologist and one non-ophthalmologist (group 3)
Number of subjects: 100
Study 24194508 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg four times a day)
Number of subjects: 14
Study 22435658 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk allergy (CMA) group
Number of subjects: 95
Study 22435658 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CM skin prick test (SPT)
Number of subjects: 95
Study 22435658 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA group
Number of subjects: 95
Study 22435658 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive egg SPT
Number of subjects: 95
Study 20578532 — intervention group
Group type: EXPERIMENTAL
Intervention: Live probiotic
Number of subjects: 43
Study 20578532 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed probiotic
Number of subjects: 43
Study 18829776 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 208
Study 18829776 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 208
Study 15929052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1 x 10(8) autologous MSCs (n = 5)
Number of subjects: 30
Study 15929052 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 30
Study 11923805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol fumarate
Number of subjects: 28
Study 11923805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10102961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg, metronidazole 500 mg, and clarithromycin 500 mg, all twice daily for 1 week (RMC)
Number of subjects: 201
Study 10102961 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 1000 mg substituted for clarithromycin (RMA)
Number of subjects: 201
Study 7572746 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula with dephytinization
Number of subjects: 8
Study 7572746 — intervention group
Group type: COMPARATOR
Intervention: Soy formula with native phytic acid
Number of subjects: 8
Study 7572746 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula with ascorbic acid at 625 mumol/L (110 mg/L)
Number of subjects: 8
Study 7572746 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula with ascorbic acid at 1250 mumol/L (220 mg/L)
Number of subjects: 8
Study 2405811 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic concentric training on a Cybex II+ isokinetic dynamometer, three days weekly for six weeks, five sets of ten maximal effort knee extensions at 1.05 rad/s
Number of subjects: 16
Study 2405811 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 7441660 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen (750 mg/d)
Number of subjects: 0
Study 7441660 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin (100 mg/d)
Number of subjects: 0
Study 7441660 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 0
Study 31773764 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated self-care intervention targeting adults with concomitant HF and T2D for 6 months
Number of subjects: 180
Study 31773764 — intervention group
Group type: COMPARATOR
Intervention: Oral antiglycemic medication and insulin
Number of subjects: 180
Study 31773764 — intervention group
Group type: COMPARATOR
Intervention: History of depression
Number of subjects: 180
Study 31773764 — intervention group
Group type: COMPARATOR
Intervention: Cardiac pacemaker
Number of subjects: 180
Study 31773764 — intervention group
Group type: COMPARATOR
Intervention: Digitalis
Number of subjects: 180
Study 30907034 — intervention group
Group type: EXPERIMENTAL
Intervention: FMPBE (250 mg/day, n = 21)
Number of subjects: 40
Study 30907034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mg starch/day, n = 19)
Number of subjects: 40
Study 29084159 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating out frequency among females
Number of subjects: 4595
Study 29084159 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for eating out
Number of subjects: 4595
Study 29084159 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorite places for eating out
Number of subjects: 4595
Study 29084159 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of nutrition and food safety
Number of subjects: 4595
Study 29084159 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand for nutrition and food safety knowledge
Number of subjects: 4595
Study 29084159 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with monthly living expenses
Number of subjects: 4595
Study 26030346 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 80 mg/day
Number of subjects: 322
Study 26030346 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 160 mg/day
Number of subjects: 322
Study 26030346 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 240 mg/day
Number of subjects: 322
Study 26030346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 23769297 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-month physical activity and dietary intervention
Number of subjects: 360
Study 22484807 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian activity rhythm parameters (acrophase, amplitude, 24-h autocorrelation coefficient)
Number of subjects: 156
Study 22484807 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian activity rhythm parameters in obese women
Number of subjects: 156
Study 19836748 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat patch mesh
Number of subjects: 0
Study 19836748 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional mesh (plug)
Number of subjects: 0
Study 19836748 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-sided patch
Number of subjects: 0
Study 19836748 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional studies
Number of subjects: 0
Study 17691589 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-59 labeled iron(III)-hydroxide polymaltose complex (IPC, Maltofer), 100 mg elemental iron
Number of subjects: 22
Study 17691589 — intervention group
Group type: COMPARATOR
Intervention: Fe-59 labeled iron(III)-hydroxide polymaltose complex (IPC, Maltofer) combined with 600 mg aluminium hydroxide (10 ml)
Number of subjects: 22
Study 15761783 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg bid)
Number of subjects: 100
Study 15761783 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg bid)
Number of subjects: 100
Study 15761783 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of N-acetylcysteine and Vitamin C (600 mg NAC and 500 mg Vitamin C bid)
Number of subjects: 100
Study 15761783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15761783 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, Vitamin C, and NAC/Vitamin C combination
Number of subjects: 100
Study 12847065 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-proBNP)
Number of subjects: 6809
Study 12847065 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP and creatinine clearance
Number of subjects: 6809
Study 12847065 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T, creatinine clearance, and ST-segment depression
Number of subjects: 6809
Study 10421142 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of sulbactam plus ampicillin (group 1)
Number of subjects: 120
Study 10421142 — intervention group
Group type: COMPARATOR
Intervention: 2 g of cefazolin (group 2)
Number of subjects: 120
Study 8889287 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa
Number of subjects: 12
Study 8889287 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 12
Study 8889287 — intervention group
Group type: COMPARATOR
Intervention: Control (neuroleptic drugs)
Number of subjects: 12
Study 1987786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood temperature of 28 degrees C
Number of subjects: 20
Study 1987786 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative blood temperature of 20 degrees C
Number of subjects: 20
Study 7072873 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory aids
Number of subjects: 1200
Study 30921241 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 60
Study 30921241 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anesthesia (DES)
Number of subjects: 60
Study 27614769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 72
Study 27614769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26427987 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with combined application of MMC (0.4 mg/ml for 3 min) and bevacizumab (2.5 mg in 0.2 ml)
Number of subjects: 12
Study 26427987 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with application of MMC (0.4 mg/ml for 3 min) only
Number of subjects: 12
Study 24238650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 60
Study 24238650 — intervention group
Group type: COMPARATOR
Intervention: Non-Tourniquet
Number of subjects: 60
Study 22119634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 15 mg (Group B)
Number of subjects: 138
Study 22119634 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 12 mg with fentanyl 15 μg (Group BF)
Number of subjects: 138
Study 19221727 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg three times daily for 14 days
Number of subjects: 12
Study 18372698 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise countermeasure (Ex: treadmill under LBNP and flywheel)
Number of subjects: 24
Study 18372698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition (Nut: daily protein supplement)
Number of subjects: 24
Study 18372698 — intervention group
Group type: COMPARATOR
Intervention: Control (Co)
Number of subjects: 24
Study 18372698 — intervention group
Group type: EXPERIMENTAL
Intervention: Non finisher group
Number of subjects: 24
Study 18372698 — intervention group
Group type: EXPERIMENTAL
Intervention: Finisher group
Number of subjects: 24
Study 16356437 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture
Number of subjects: 39
Study 16356437 — intervention group
Group type: COMPARATOR
Intervention: Air-oxygen mixture (control group)
Number of subjects: 39
Study 14764406 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 14
Study 14764406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9541719 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (200-600 mg once daily)
Number of subjects: 0
Study 9541719 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone added to sulfonylureas or insulin
Number of subjects: 0
Study 9541719 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 0
Study 7811181 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2114133 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners receiving extended waiting time information for hospital consultation and treatment in general surgery.
Number of subjects: 0
Study 2114133 — intervention group
Group type: COMPARATOR
Intervention: Matched control group not receiving extended waiting time information.
Number of subjects: 0
Study 380952 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% (2.5 mg) reproterol aerosol
Number of subjects: 30
Study 380952 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% (5 mg) reproterol aerosol
Number of subjects: 30
Study 380952 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 31033035 — intervention group
Group type: EXPERIMENTAL
Intervention: Short abutment (1 mm)
Number of subjects: 70
Study 31033035 — intervention group
Group type: COMPARATOR
Intervention: Long abutment (3 mm)
Number of subjects: 70
Study 28264429 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially-sweetened beverages (ASB)
Number of subjects: 26
Study 28264429 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened beverages (SSB)
Number of subjects: 26
Study 25835492 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3, 30000 IU given orally once weekly for 8 weeks
Number of subjects: 44
Study 25835492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 24079838 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative psychotherapeutic nursing home programme (IRR)
Number of subjects: 100